zinc finger protein 318Genealiases: HRIHFB2436 · TZF · ZFP318
Q-omics provides the consensus-scored ZNF318 profile across patient tissues and cancer cell-line models. ZNF318 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF318 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, ZNF318 protein abundance shows 25,027 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, HNSC, and LSCC as cancer lineages where ZNF318 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF318 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF318 survival associations across molecular data types. ZNF318 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF318 RNA expression–survival associations across cancer types. High ZNF318 expression shows unfavorable associations in MESO, KICH and ACC, but favorable associations in KIRC, UCS and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF318 RNA expression.
This table summarizes ZNF318 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for ZNF318. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF318 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, LIHC, STAD and LUSC. The HNSC box plot shows higher ZNF318 RNA expression in tumor versus normal tissue (log2 FC = +1.056, t-test p < 0.001).
This table shows molecular features associated with ZNF318 in patient tissues and cancer cell lines. In patient samples, ZNF318 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF318 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Lymphoma.
